top of page

Infectious Disease & Sepsis

Public·458 members

Prolonged higher dose methylprednisolone vs. conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS)



  • 677 patients were included in the study and randomly assigned to either methylprednisolone 80 mg as a continuous daily infusion for 8 days followed by slow tapering or dexamethasone 6 mg daily for up to 10 days in adult patients with COVID-19 pneumonia requiring oxygen or noninvasive respiratory support

  • There was no significant difference in mortality between the two groups by day 28

  • Methylprednisolone did not reduce mortality at 28 days compared to conventional dexamethasone in COVID-19 pneumonia

About

Welcome to the group! Connect with other members, get updates and share media.

Members

bottom of page